Ashvattha Therapeutics, Inc.
Pharmaceutical ManufacturingView the employees at
Ashvattha Therapeutics, Inc.-
Madhuri Chattopadhyay in vitro pharmacology | neurodegeneration | assay development | drug discovery
-
Palo Alto, California, United States
-
Rising Star
-
San Francisco Bay Area
-
Rising Star
Brandon Nicholas Tong Logistics/CMC Coordinator-
San Jose, California, United States
-
Top 10%
Overview
Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.
-